首页> 外文期刊>RSC Advances >Rational design and synthesis of novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent
【24h】

Rational design and synthesis of novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent

机译:新型2-(取代-2H-铬-3-基)-5-芳基-1H-咪唑衍生物作为抗血管生成和抗癌剂的合理设计与合成

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Based on earlier proven pharmacophore analogues of cancer a novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazoles (13-16) were rationally designed and synthesized by the reaction of chromene-3-carboxylic acids (10a-d) with substituted acyl bromides in the presence of TEA followed by refluxing with NH4OAc in toluene. Compounds 13-16 were screened in vitro for the inhibition of KRAS/Wnt and their anti-angiogenesis properties. Compound 16f has been identified as a potent anti-angiogenesis molecule, which can be considered as a new lead structure. The molecular docking analysis displayed the higher binding affinity of 16f with KRAS, Wnt and VEGF.
机译:基于癌症的较早药效基团类似物,通过色烯-3-羧酸的反应,合理设计和合成了新型的2-(取代的2H-铬-3-基)-5-芳基-1H-咪唑(13-16)。 TEA的存在下,用取代的酰基溴将丙烯酸(10a-d)取代,然后与NH4OAc在甲苯中回流。体外筛选化合物13-16对KRAS / Wnt的抑制作用及其抗血管生成特性。化合物16f已被鉴定为有效的抗血管生成分子,可以认为是新的先导结构。分子对接分析显示16f与KRAS,Wnt和VEGF的结合亲和力更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号